C9orf72 promoter hypermethylation is neuroprotective

Objective: To use in vivo neuroimaging and postmortem neuropathologic analysis in C9orf72 repeat expansion patients to investigate the hypothesis that C9orf72 promoter hypermethylation is neuroprotective and regionally selective. Methods: Twenty patients with a C9orf72 repeat expansion participating in a high-resolution MRI scan and a clinical examination and a subset of patients (n = 11) were followed longitudinally with these measures. Gray matter (GM) density was related to C9orf72 promoter hypermethylation using permutation-based testing. Regional neuronal loss was measured in an independent autopsy series (n = 35) of C9orf72 repeat expansion patients. Results: GM analysis revealed that hippocampus, frontal cortex, and thalamus are associated with hypermethylation and thus appear to be relatively protected from mutant C9orf72. Neuropathologic analysis demonstrated an association between reduced neuronal loss and hypermethylation in hippocampus and frontal cortex. Longitudinal neuroimaging revealed that hypermethylation is associated with reduced longitudinal decline in GM regions protected by hypermethylation and longitudinal neuropsychological assessment demonstrated that longitudinal decline in verbal recall is protected by hypermethylation. Conclusions: These cross-sectional and longitudinal neuroimaging studies, along with neuropathologic validation studies, provide converging evidence for neuroprotective properties of C9orf72 promoter hypermethylation. These findings converge with prior postmortem studies suggesting that C9orf72 promoter hypermethylation may be a neuroprotective target for drug discovery.

[1]  L. Petrucelli,et al.  Characterization of DNA hypermethylation in the cerebellum of c9FTD/ALS patients , 2014, Brain Research.

[2]  L. Ungar,et al.  The power of neuroimaging biomarkers for screening frontotemporal dementia , 2014, Human brain mapping.

[3]  D. Mann,et al.  Brain distribution of dipeptide repeat proteins in frontotemporal lobar degeneration and motor neurone disease associated with expansions in C9ORF72 , 2014, Acta neuropathologica communications.

[4]  P. S. St George-Hyslop,et al.  Hypermethylation of the CpG-island near the C9orf72 G₄C₂-repeat expansion in FTLD patients. , 2014, Human molecular genetics.

[5]  Brian B. Avants,et al.  Genetic and neuroanatomic associations in sporadic frontotemporal lobar degeneration , 2014, Neurobiology of Aging.

[6]  D. Irwin,et al.  C9orf72 hypermethylation protects against repeat expansion-associated pathology in ALS/FTD , 2014, Acta Neuropathologica.

[7]  I. Mackenzie,et al.  The neuropathology associated with repeat expansions in the C9ORF72 gene , 2014, Acta Neuropathologica.

[8]  Roberto Gasparotti,et al.  Effect of TMEM106B polymorphism on functional network connectivity in asymptomatic GRN mutation carriers. , 2014, JAMA neurology.

[9]  Brian B. Avants,et al.  Sparse canonical correlation analysis relates network-level atrophy to multivariate cognitive measures in a neurodegenerative population , 2014, NeuroImage.

[10]  Susan Byrne,et al.  Basal ganglia involvement in amyotrophic lateral sclerosis , 2013, Neurology.

[11]  M. Grossman,et al.  Development and validation of pedigree classification criteria for frontotemporal lobar degeneration. , 2013, JAMA neurology.

[12]  L. Petrucelli,et al.  Reduced C9orf72 gene expression in c9FTD/ALS is caused by histone trimethylation, an epigenetic event detectable in blood , 2013, Acta Neuropathologica.

[13]  S. Lorenzl,et al.  Dipeptide repeat protein pathology in C9ORF72 mutation cases: clinico-pathological correlations , 2013, Acta Neuropathologica.

[14]  C. Caltagirone,et al.  Cognitive Reserve in Granulin-Related Frontotemporal Dementia: from Preclinical to Clinical Stages , 2013, PloS one.

[15]  A. Bokde,et al.  Multiparametric MRI study of ALS stratified for the C9orf72 genotype , 2013, Neurology.

[16]  Murray Grossman,et al.  Stages of pTDP‐43 pathology in amyotrophic lateral sclerosis , 2013, Annals of neurology.

[17]  E. Rogaeva,et al.  Hypermethylation of the CpG island near the G4C2 repeat in ALS with a C9orf72 expansion. , 2013, American journal of human genetics.

[18]  Robert V Farese,et al.  The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: The next therapeutic frontier) , 2013, Alzheimer's & Dementia.

[19]  Jonathan M. Bekisz,et al.  Cognitive decline and reduced survival in C9orf72 expansion frontotemporal degeneration and amyotrophic lateral sclerosis , 2012, Journal of Neurology, Neurosurgery & Psychiatry.

[20]  Nick C Fox,et al.  Longitudinal neuroimaging and neuropsychological profiles of frontotemporal dementia with C9ORF72 expansions , 2012, Alzheimer's Research & Therapy.

[21]  John L. Robinson,et al.  Pattern of ubiquilin pathology in ALS and FTLD indicates presence of C9ORF72 hexanucleotide expansion , 2012, Acta Neuropathologica.

[22]  A. Al-Chalabi,et al.  Cognitive and clinical characteristics of patients with amyotrophic lateral sclerosis carrying a C9orf72 repeat expansion: a population-based cohort study , 2012, The Lancet Neurology.

[23]  J. Hardy,et al.  Clinico-pathological features in amyotrophic lateral sclerosis with expansions in C9ORF72. , 2012, Brain : a journal of neurology.

[24]  C. Jack,et al.  Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics , 2012, Brain : a journal of neurology.

[25]  Nick C Fox,et al.  Frontotemporal dementia with the C9ORF72 hexanucleotide repeat expansion: clinical, neuroanatomical and neuropathological features , 2012, Alzheimer's & Dementia.

[26]  Murray Grossman,et al.  The Philadelphia Brief Assessment of Cognition (PBAC): A Validated Screening Measure for Dementia , 2011, The Clinical neuropsychologist.

[27]  David Heckerman,et al.  A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD , 2011, Neuron.

[28]  Bruce L. Miller,et al.  Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALS , 2011, Neuron.

[29]  Nick C Fox,et al.  Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. , 2011, Brain : a journal of neurology.

[30]  B. Miller,et al.  Classification of primary progressive aphasia and its variants , 2011, Neurology.

[31]  Arno Klein,et al.  A reproducible evaluation of ANTs similarity metric performance in brain image registration , 2011, NeuroImage.

[32]  B. Boeve,et al.  Clinical, neuroimaging and neuropathological features of a new chromosome 9p-linked FTD-ALS family , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[33]  Jennifer L. Whitwell,et al.  MRI Correlates of Protein Deposition and Disease Severity in Postmortem Frontotemporal Lobar Degeneration , 2009, Neurodegenerative Diseases.

[34]  M. Freedman,et al.  Consensus criteria for the diagnosis of frontotemporal cognitive and behavioural syndromes in amyotrophic lateral sclerosis , 2009, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[35]  Brian B. Avants,et al.  Symmetric diffeomorphic image registration with cross-correlation: Evaluating automated labeling of elderly and neurodegenerative brain , 2008, Medical Image Anal..

[36]  Cheryl L. Dahle,et al.  Regional brain changes in aging healthy adults: general trends, individual differences and modifiers. , 2005, Cerebral cortex.

[37]  N. Tzourio-Mazoyer,et al.  Automated Anatomical Labeling of Activations in SPM Using a Macroscopic Anatomical Parcellation of the MNI MRI Single-Subject Brain , 2002, NeuroImage.

[38]  Thomas E. Nichols,et al.  Nonparametric permutation tests for functional neuroimaging: A primer with examples , 2002, Human brain mapping.

[39]  M. Grossman,et al.  Hypermethylation of repeat expanded C9orf72 is a clinical and molecular disease modifier , 2014, Acta Neuropathologica.